Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2006-06-23
2010-11-09
Rao, Manjunath N (Department: 1656)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C604S508000
Reexamination Certificate
active
07829082
ABSTRACT:
A composition useful for removal of fibrin-bound blood clots from a catheter comprises water, a fibrinolytically effective amount of a plasminogen activator, and a preservatively effective amount of a bacteriostatic organic alcohol. The composition does not comprise a chelating agent.
REFERENCES:
patent: 5019096 (1991-05-01), Fox, Jr. et al.
patent: 5091442 (1992-02-01), Milner
patent: 5362754 (1994-11-01), Raad et al.
patent: 5363754 (1994-11-01), Coles et al.
patent: 5385732 (1995-01-01), Anderson et al.
patent: 5399158 (1995-03-01), Lauer et al.
patent: 5447724 (1995-09-01), Helmus et al.
patent: 5509896 (1996-04-01), Carter
patent: 5612029 (1997-03-01), Bennett et al.
patent: 5688516 (1997-11-01), Raad et al.
patent: 5772640 (1998-06-01), Modak et al.
patent: 5824049 (1998-10-01), Ragheb et al.
patent: 5837688 (1998-11-01), Gelfand
patent: 5849736 (1998-12-01), Wityak et al.
patent: 5865178 (1999-02-01), Yock
patent: 5932299 (1999-08-01), Katoot
patent: 6087375 (2000-07-01), Bridon et al.
patent: 6124277 (2000-09-01), Schacht et al.
patent: 6166007 (2000-12-01), Sodemann
patent: 6174537 (2001-01-01), Khan
patent: 6187768 (2001-02-01), Welle et al.
patent: 6206914 (2001-03-01), Soykan et al.
patent: 6231605 (2001-05-01), Ku
patent: 6258797 (2001-07-01), Lehner
patent: 6284247 (2001-09-01), Goeddel et al.
patent: 6346517 (2002-02-01), Wong et al.
patent: 6350251 (2002-02-01), Prosl et al.
patent: 2001/0021811 (2001-09-01), Yock
patent: 2001/0031981 (2001-10-01), Evans et al.
patent: 2002/0082582 (2002-06-01), Finch et al.
patent: 2003/0206906 (2003-11-01), Semba
patent: 2005/0215978 (2005-09-01), Ash
patent: 2006/0257390 (2006-11-01), Semba
patent: 2007/0014779 (2007-01-01), Semba
patent: 42810/89 (1992-10-01), None
patent: 882461 (1998-12-01), None
patent: 1040841 (2000-10-01), None
patent: 1 060 747 (2000-12-01), None
patent: 1 442 753 (2004-08-01), None
patent: 1 688 154 (2006-08-01), None
patent: 08-503400 (1996-04-01), None
patent: WO 94/10838 (1994-05-01), None
patent: WO-95/14683 (1995-06-01), None
patent: WO-98/28326 (1998-07-01), None
patent: WO-00/53264 (2000-09-01), None
patent: WO 01/85249 (2001-11-01), None
patent: WO-03/045466 (2003-06-01), None
patent: WO-03/045466 (2003-06-01), None
patent: WO-2006/049813 (2006-05-01), None
patent: WO-2006/049813 (2006-05-01), None
patent: WO-2008/070353 (2008-06-01), None
patent: WO-2008/070353 (2008-06-01), None
Antani, M.R., “Catheter-directed thrombolysis for the treatment of acute deep venous thrombosis”Supplement to Applied Radiologypp. 29-35 (Jul. 2001).
Ashton, J., et al., “Effects of heparin versus saline solution on intermittent infusion device irrigation”Heart&Lung: Journal of Critical Care19(6): 608-612 (Nov. 1990).
Boorgu et al., “Adjunctive Antibiotic/Anticoagulant Lock Therapy in the Treatment of Bacteremia Associated with the Use of a Subcutaneously Implanted Nemodialysis Access Device.”ASAIO J.46:767-770 (Nov. 2000).
Buturovic et al., “Filling Hemodialysis Catheters in the Interdialytic Period: Heparin Versus Citrate Versus Polygeline: A Prospective Randomized Study”Artificial Organs22:945-947 (1998).
Darouiche and Raad, “Prevention of Catheter-Related Infections: The Skin”Nutrition(Suppl.) 13(4):26S-29S (1997).
Food and Drug Administration, “FDA Issues Warning on Tricitrasol Dialysis Catheter Anticoagulant”FDA Talk Paper T00-16(Apr. 14, 2000).
Garrelts, James C., et al., “Comparison of heparin and 0.9% sodium chloride injection of indwelling intermittent i.v. devices”Clinical Pharmacy8:34-39 (Jan. 1989) Abstract.
Greco et al., “Patency of a Small Vessel Prosthesis Bonded to Tissue Plasminogen Activator and Iloprost.”Ann. Vasc. Surg.9(2): 140-145 (1995).
Haire et al., “Urokinase Versus Recombinant Tissue Plasminogen Activator in Thrombosed Central Venous Catheters: A Double-Blinded, Randomized Trial”Thromb. Haemost.72:543-547 (1994).
Henrickson et al., “Prevention of Central Venous Catheter-Related Infections and Thrombotic Events in Immunocompromised Children by the Use of Vancomycin/Ciprofloxacin/Heparin Flush Solution: A Randomized, Multicenter, Double-Blind Trial” J. Clin. Oncol. 18:1269-1278 (2000).
Kamal et al., “Reduced Intravascular Catheter Infection by Antibiotic Bonding: A Prospective Randomized, Controlled Trial”J. Amer. Med. Assc.265:2364-2368 (May 1991).
Karaaslan, H., et al., “Risk of heparin lock-related bleeding when using indwelling venous catheter in haemodialysis”Nephrol Dial Transplant16:2072-2074 (2001).
Karnes, H. T. et al., “Benzyl Alcohol Interference from Heparin Lock Flush Solutions in a High Pressure Liquid Chromatographic Procedure for Mezlocillin”Therapeutic Drug Monitoring, New York:Raven Press, Ltd. vol. 9(4):456-460 (1987).
Lokich et al., “Complications and Management of Implaned Venous Access Catheters.”J. Clin. Oncol.3:710-717 (1985).
Ouriel at al., “Comparison of streptokinase, urokinase, and recombinant tissue plasminogen activator in an in vitro model of venous thrombolysis”Journal of Vascular Surgery22:593-597 (Nov. 1995).
Patel et al., “Successful Use of Low Dose r-Hirudin (Refludan)for Recurrent Dialysis Catheter Thrombosis in a Patient with Heparin Induced Thrombocytopenia.”Thromb. Haemost.82:1205-1206 (1999).
Purchase and Gault., “Hemodialysis with a Permcath Kept Open with Streptokinase and Later Citrate in a Heparin-Sensitive Patient.”Nephron58:119-120 (1991).
Root at al., “Inhibitory Effect of Disodium EDTA Upon the Growth of Staphylococcus epidermidis In Vitro: Relation to Infection Prophylaxis of Hickman Catheters.”Antimicrob. Agents Chemother.32:1627-1631 (Nov. 1988).
Rubin., “Local Installation of Small Doses of Streptokinase for Treatment of Thrombotic Occlusions of Long-Term Access Catheters.”J. Clin. Oncol.1:572-573 (Sep. 1983).
Schenk et al., “Recombinant Tissue Plasminogen Activator is a Useful Alternative to Heparin in Priming Quinton Permeath.”Amer. J. Kidney Diseases35:130-136 (Jan. 2000).
Schwartz et al., “Prevention of Bacteremia Attributed to Luminal Colonization of Tunneled Central Venous Catheters With Vancomycin-Susceptible Organisms.”J. Clin. Oncology8:1591-1597 (Sep. 1990).
Skrzydlewska, E., Worowski, Krzysztof, “Effect of ethanol and acetaldehyde on fibrinolytic system in vitro”Roczniki Akademii Medyczne w Bialymstoku29-30:163-173 (-1985 1984).
Sodemann et al., “Gentamicin/Sodium-Citrate Mixture as Antibiotic-Lock Technique for Salvage and Prevention of Catheter-Related Infections- A Four Year Trial.”30th Annual Meeting of American Society of Nephrology, San Antonio, TX (A0811, S064 (PS)) pp. 173A (Nov. 2-5, 1997).
Sodemann et al., “Two Years' Experience with Dialock and CLS (A New Antimicrobial Lock Solution)”Blood Purif. 19:251-254 (2001).
Stas et al., “Trisodium Citrate 30% vs Heparin 5% as Catheter Lock in the Interdialytic Period in Twin- or Double-Lumen Dialysis Catheters for Intermittent Haemodialysis.”Nephrol. Dial. Transplant. Purif.19:251-254 (2001).
Tang, M., “Bacteriostatic Saline Flush Interferes with Sodium Measurement on the Ektachem 700”Clinical Chemistry39(9):2032 (1993).
Vercaigne et al., “Antibiotic-Heparin Lock: In Vitro Antibiotic Stability Combined with Heparin in a Central Venous Catheter.”Pharmcotherapy20(4):394-399 (Apr. 2000).
Wiernikowski et al., “Bacterial Colonization of Tunneled Right Atrial Catheters in Pediatric Oncology: A Comparison of Sterile Saline and Bacteriostatic Saline Flush Solutions.”Am. J. Pediat. Hematol. Oncol. 13:137-140 (1991).
Woodhouse et al., “Lysis of Surface-Localized Fibrin Clots by Absorbed Plasminogen in the Presence of Tissue Plasminogen Activator.”Biomaterials17:75-77 (1996).
Zhou et al., “Development of a Multiple-Drug Delivery Implant for Intraocular Management of Prolifera
Genentech Inc.
Morrison & Foerster / LLP
Rao Manjunath N
Tsay Marsha M.
LandOfFree
Catheter composition and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Catheter composition and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Catheter composition and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4172105